The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.
After years of awaiting results from clinical trials that included BTKi in frontline treatment combinations, the ECHO trial led to the FDA’s approval of the first BTKi in combination with chemoimmunotherapy.
Dr. Alderuccio highlighted data from the ECHELON-3 trial supporting FDA-approved brentuximab vedotin with lenalidomide and rituximab as an option that can be provided in any clinic. Other approved choices show limited durability.
These findings are clinically relevant in a highly curable disease that frequently affects younger adults. When selecting a treatment regimen for this patient population, it is important to balance durable disease control with preservation of physical function and QoL.
My day-to-day is pretty much operational and involves a little bit of everything. When I first started with SOHO 15 years ago, we all wore so many different hats; nobody did just one thing.
Amifostine and uproleselan also showed “meaningful promise” for reducing mucositis and delaying severe diarrhea and improving GI quality of life, respectively, but require prospective validation, wrote the study’s authors, led by Vraj Rangrej, MD, of Mayo Clinic in Jacksonville, Florida.
Dr. O’Brien, a founding member of the society, has contributed far beyond her scientific expertise. Known for her dedication and commitment to the field, she has supported SOHO’s growth and mission since the society’s earliest days.
SOHO Insider is the official media platform of the Society of Hematologic Oncology. The SOHO Insider Editorial Board is comprised of leading hematologists. Learn more about our editorial board and SOHO Insider platforms.
To access the SOHO Career Center click the following link.
